I think there's some confusion about "Nanostring". It was never part of CytoDyn, Prostagene, or had any Pestell control in it. It was a company that CytoDyn had some contact with during Pestell's tenure. Plus they were subpoenaed during CytoDyn's lawsuit with Pestell. (19-cv-1563 https://www.courtlistener.com/docket/16099689...todyn-inc)

Here's a quote from the 3rd amended complaint:

Quote:

---

158. Dr. Pestell was also unable to move forward with certain studies for which he was responsible because the Company failed to sign the necessary contracts.
159. For example, the ProstaGene Prognostic Test could not move forward until the Company hired bioinformatician Dr. Andrew Kossenkov to generate data for the Company’s 510(k) application to the FDA and for the Company’s contemplated licensing agreement with NanoString. But Dr. Kossenkov’s hiring was delayed because, despite having received the most recent iteration of Dr. Kossenkov’s contract from his counsel on June 13, 2019, as of July 22, 2019 the Company still had not engaged in further discussions regarding the contract or signed it.

---

Nanostring Technologies was delisted from the NASDAQ last year (Feb 2024)
https://ir.nasdaq.com/news-releases/news-rele...k-holdings
Their website:
https://nanostring.com/ (now a Bruker company)

More info
https://en.wikipedia.org/wiki/NanoString_Technologies

Of note, Brian Brothen worked there for a while...now he works for everyone's favorite "Incel".
https://theorg.com/org/incelldx/org-chart/brian-brothen